If the alternative drug was accepted less than 90%, the drug price negotiation was omitted. It was confirmed which was conditionally approved by the Pharmaceutical benefit evaluation committee in October, accepted the results and moved to the stage of negotiation.

This drug is used to treat bleeding in patients with adult acquired hemophilia A.l According to the industry on the 16th, Obizur was recognized for its salary suitability by accepting less than the evaluation amount of the weak level. The Pharmaceutical Review Committee, held on October 12, determined that there is a suitable salary for Obijour if it is accepted below the assessed amount. It is interpreted as a condition that the weighted av